Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

100.76
-0.1300-0.13%
Post-market: 100.760.00000.00%19:30 EDT
Volume:92.51K
Turnover:9.33M
Market Cap:4.14B
PE:-97.99
High:101.63
Open:101.54
Low:100.57
Close:100.89
52wk High:107.69
52wk Low:85.36
Shares:41.10M
Float Shares:41.10M
Volume Ratio:0.86
T/O Rate:0.23%
Dividend:1.44
Dividend Rate:1.43%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.07
PE(LYR):-97.99

Loading ...

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

Dow Jones
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

UnitedHealth (UNH) Gets a Buy from Bernstein

TIPRANKS
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

CurveBeam AI Details Director Appointment and Equity Interests

TIPRANKS
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

DBV Technologies Steps Up Investor Outreach Ahead of Key Food Allergy Trial Milestones

TIPRANKS
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

Press Release: PatientIQ Raises $30 Million Series C to Power the Next Generation of Patient-Reported Outcomes Intelligence

Dow Jones
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03